The tumor necrosis factor inhibitor (TNFi) infliximab (IFX) and the α4/β7 integrin blocker vedolizumab (VDZ) are recommended first-line biologic treatments for patients with moderately to severely active inflammatory bowel disease (IBD) [1,2]. Here, TNF is linked to inflammatory bowel disease.